Structural framework for covalent inhibition of Clostridium botulinum neurotoxin a by targeting Cys165

Journal of Biological Chemistry

Volumn 287, Issue 40, 2012, Pages 33607-33614

  Stura, Enrico A ^a   Le Roux, Laura ^a   Guitot, Karine ^a   Garcia, Sandra ^a   Bregant, Sarah ^a   Beau, Fabrice ^a   Vera, Laura ^a   Collet, Guillaume ^a   Ptchelkine, Denis ^a   Bakirci, Huseyin ^a   Dive, Vincent ^a  

^a Institute Frederic Joliot   (France)

Author keywords

[No Author keywords available]

Indexed keywords

BIOTHREAT AGENTS; CATALYTIC DOMAINS; CLOSTRIDIUM BOTULINUM NEUROTOXIN; COVALENT COMPLEX; COVALENT MODIFICATIONS; ENZYME ACTIVE SITES; ENZYME CATALYSIS; HUMAN PATHOGENS; METALLOPROTEASES; PEPTIDE MASS FINGERPRINTING; PROTEIN DATABASE; SELECTIVE INHIBITORS; SITE DIRECTED MUTAGENESIS; STRUCTURAL FRAMEWORKS; STRUCTURAL STUDIES; SULFONYL GROUPS; X-RAY STRUCTURE; ZINC IONS;

AMINO ACIDS; X RAY CRYSTALLOGRAPHY; ZINC;

ENZYMES;

BOTULINUM TOXIN A; CYSTEINE; PROTEINASE; UNCLASSIFIED DRUG; ZINC PROTEASE;

ARTICLE; CATALYSIS; CHEMICAL COMPOSITION; CHEMICAL MODIFICATION; CONTROLLED STUDY; COVALENT BOND; CRYSTAL STRUCTURE; ENZYME ACTIVITY; PRIORITY JOURNAL; SITE DIRECTED MUTAGENESIS; STRUCTURE ANALYSIS; TOXIN STRUCTURE;

BOTULINUM TOXINS, TYPE A; CATALYTIC DOMAIN; CHEMISTRY, PHARMACEUTICAL; CLOSTRIDIUM BOTULINUM; CRYSTALLOGRAPHY, X-RAY; CYSTEINE; DRUG DESIGN; ENZYME INHIBITORS; HUMANS; KINETICS; MUTAGENESIS, SITE-DIRECTED; PEPTIDE HYDROLASES; PEPTIDES; PROTEIN STRUCTURE, TERTIARY; RECOMBINANT PROTEINS; SYNAPTOSOMAL-ASSOCIATED PROTEIN 25; ZINC;

CLOSTRIDIUM BOTULINUM;

EID: 84866925592     PISSN: 00219258     EISSN: 1083351X     Source Type: Journal    
DOI: 10.1074/jbc.M112.396697     Document Type: Article

References (38)

1. Oguma, K., Fujinaga, Y., and Inoue, K. (1995) Structure and function of Clostridium botulinum toxins. Microbiol. Immunol. 39, 161-168
2. Willis, B., Eubanks, L. M., Dickerson, T. J., and Janda, K. D. (2008) The strange case of the botulinum neurotoxin. Using chemistry and biology to modulate the most deadly poison. Angew Chem. Int. Ed. Engl. 47, 8360-8379
3. Arnon, S. S., Schechter, R., Inglesby, T. V., Henderson, D. A., Bartlett, J. G., Ascher, M. S., Eitzen, E., Fine, A. D., Hauer, J., Layton, M., Lillibridge, S., Osterholm, M. T., O'Toole, T., Parker, G., Perl, T. M., Russell, P. K., Swerdlow, D. L., and Tonat, K. (2001) Botulinum toxin as a biological weapon. Medical and public health management. JAMA 285, 1059-1070 (Pubitemid 32176420)
4. Simpson, L. L. (2004) Identification of the major steps in botulinum toxin action. Annu. Rev. Pharmacol. Toxicol. 44, 167-193
5. Li, B., Peet, N. P., Butler, M. M., Burnett, J. C., Moir, D. T., and Bowlin, T. L. (2011) Small molecule inhibitors as countermeasures for botulinum neurotoxin intoxication. Molecules 16, 202-220
6. Schmidt, J. J., Stafford, R. G., and Bostian, K. A. (1998) Type A botulinum neurotoxin proteolytic activity. Development of competitive inhibitors and implications for substrate specificity at the S1′ binding subsite. FEBS Lett. 435, 61-64 (Pubitemid 28432015)
7. Zuniga, J. E., Schmidt, J. J., Fenn, T., Burnett, J. C., Araç, D., Gussio, R., Stafford, R. G., Badie, S. S., Bavari, S., and Brunger, A. T. (2008) A potent peptidomimetic inhibitor of botulinum neurotoxin serotype A has a very different conformation than SNAP-25 substrate. Structure 16, 1588-1597
8. Kumaran, D., Rawat, R., Ahmed, S. A., and Swaminathan, S. (2008) Substrate binding mode and its implication on drug design for botulinum neurotoxin A. PLoS Pathog. 4, e1000165
9. Hale, M., Oyler, G., Swaminathan, S., and Ahmed, S. A. (2011) Basic tetrapeptides as potent intracellular inhibitors of type A botulinum neurotoxin protease activity. J. Biol. Chem. 286, 1802-1811
10. Burnett, J. C., Ruthel, G., Stegmann, C. M., Panchal, R. G., Nguyen, T. L., Hermone, A. R., Stafford, R. G., Lane, D. J., Kenny, T. A., McGrath, C. F., Wipf, P., Stahl, A. M., Schmidt, J. J., Gussio, R., Brunger, A. T., and Bavari, S. (2007) Inhibition of metalloprotease botulinum serotype A from a pseudopeptide binding mode to a small molecule that is active in primary neurons. J. Biol. Chem. 282, 5004-5014 (Pubitemid 47100957)
11. Silvaggi, N. R., Boldt, G. E., Hixon, M. S., Kennedy, J. P., Tzipori, S., Janda, K. D., and Allen, K. N. (2007) Structures of Clostridium botulinum neurotoxin serotype A light chain complexed with small-molecule inhibitors highlight active-site flexibility. Chem Biol. 14, 533-542 (Pubitemid 46765150)
12. Moe, S. T., Thompson, A. B., Smith, G. M., Fredenburg, R. A., Stein, R. L., and Jacobson, A. R. (2009) Botulinum neurotoxin serotype A inhibitors. Small-molecule mercaptoacetamide analogs. Bioorg Med. Chem. 17, 3072-3079
13. Burnett, J. C., Wang, C., Nuss, J. E., Nguyen, T. L., Hermone, A. R., Schmidt, J. J., Gussio, R., Wipf, P., and Bavari, S. (2009) Pharmacophore-guided lead optimization. The rational design of a non-zinc coordinating, sub-micromolar inhibitor of the botulinum neurotoxin serotype a metalloprotease. Bioorg Med. Chem. Lett. 19, 5811-5813
14. Li, B., Pai, R., Cardinale, S. C., Butler, M. M., Peet, N. P., Moir, D. T., Bavari, S., and Bowlin, T. L. (2010) Synthesis and biological evaluation of botulinum neurotoxin a protease inhibitors. J. Med. Chem. 53, 2264-2276
15. Breidenbach, M. A., and Brunger, A. T. (2004) Substrate recognition strategy for botulinum neurotoxin serotype A. Nature 432, 925-929 (Pubitemid 40037157)
16. Powers, J. C., Asgian, J. L., Ekici, O. D., and James, K. E. (2002) Irreversible inhibitors of serine, cysteine, and threonine proteases. Chem. Rev. 102, 4639-4750
17. Singh, J., Petter, R. C., Baillie, T. A., and Whitty, A. The resurgence of covalent drugs. Nat. Rev. Drug Discov. 10, 307-317
18. Potashman, M. H., and Duggan, M. E. (2009) Covalent modifiers. An orthogonal approach to drug design. J. Med. Chem. 52, 1231-1246
19. Li, B., Cardinale, S. C., Butler, M. M., Pai, R., Nuss, J. E., Peet, N. P., Bavari, S., and Bowlin, T. L. Time-dependent botulinum neurotoxin serotype A metalloprotease inhibitors. Bioorg Med. Chem. 19, 7338-7348
20. Kuzmic, P. (1996) Program DYNAFIT for the analysis of enzyme kinetic data. Application to HIV proteinase. Anal. Biochem. 237, 260-273
21. Kitz, R., and Wilson, I. B. (1962) Esters of methanesulfonic acid as irreversible inhibitors of acetylcholinesterase. J. Biol. Chem. 237, 3245-3249
22. Stura, E. A., Nemerow, G. R., and Wilson, I. A. (1992) Strategies in the crystallization of glycoproteins and protein complexes. J. Crystal Growth 122, 273-285
23. Stura, E. A. (1999) Strategy 3. Reverse Screening, in Crystallization of Proteins: Techniques, Strategies and Tips. A Laboratory Manual (Bergfors, T., ed) pp. 113-124, International University Line
24. Stura, E. A. (1999) Seeding, in Crystallization of Proteins: Techniques, Strategies and Tips. A Laboratory Manual (Bergfors, T., ed) pp. 141-153, International University Line
25. Leslie, A. G. (2006) The integration of macromolecular diffraction data. Acta Crystallogr. D Biol. Crystallogr. 62, 48-57
26. Vagin, A., and Teplyakov, A. (2010) Molecular replacement with MOLREP. Acta Crystallogr. D Biol. Crystallogr. 66, 22-25
27. Murshudov, G. N., Vagin, A. A., and Dodson, E. J. (1997) Refinement of macromolecular structures by the maximum-likelihood method. Acta Crystallogr. D Biol. Crystallogr. 53, 240-255 (Pubitemid 27235885)
28. McRee, D. E. (1999) XtalView/Xfit. A versatile program for manipulating atomic coordinates and electron density. J. Struct. Biol. 125, 156-165
29. Adams, P. D., Afonine, P. V., Bunkoczi, G., Chen, V. B., Davis, I. W., Echols, N., Headd, J. J., Hung, L. W., Kapral, G. J., Grosse-Kunstleve, R. W., McCoy, A. J., Moriarty, N. W., Oeffner, R., Read, R. J., Richardson, D. C., Richardson, J. S., Terwilliger, T. C., and Zwart, P. H. PHENIX. A comprehensive Python-based system for macromolecular structure solution. Acta Crystallogr. D Biol. Crystallogr. 66, 213-221
30. Stauffer, D. A., and Karlin, A. (1994) Electrostatic potential of the acetylcholine binding sites in the nicotinic receptor probed by reactions of binding-site cysteines with charged methanethiosulfonates. Biochemistry 33, 6840-6849 (Pubitemid 24190807)
31. Gomis-Ruth, F. X. (2008) Structure and mechanism of metallocarboxypeptidases. Crit. Rev. Biochem. Mol. Biol. 43, 319-345
32. Niemirowicz, G., Fernandez, D., Sola, M., Cazzulo, J. J., Aviles, F. X., and Gomis-Ruth, F. X. (2008) The molecular analysis of Trypanosoma cruzi metallocarboxypeptidase 1 provides insight into fold and substrate specificity. Mol. Microbiol. 70, 853-866
33. Ahmed, S. A., Olson, M. A., Ludivico, M. L., Gilsdorf, J., and Smith, L. A. (2008) Identification of residues surrounding the active site of type A botulinum neurotoxin important for substrate recognition and catalytic activity. Protein J. 27, 151-162 (Pubitemid 351652551)
34. 365 of the botulinum neurotoxin type a light chain are involved in transition state stabilization. Biochemistry 41, 1717-1723
35. Marino, S. M., and Gladyshev, V. N. (2010) Structural analysis of cysteine S-nitrosylation. A modified acid-based motif and the emerging role of trans-nitrosylation. J. Mol. Biol. 395, 844-859
36. Smith, A. J., Zhang, X., Leach, A. G., and Houk, K. N. (2009) Beyond picomolar affinities. Quantitative aspects of noncovalent and covalent binding of drugs to proteins. J. Med. Chem. 52, 225-233
37. Rees, D. C., Congreve, M., Murray, C. W., and Carr, R. (2004) Fragment-based lead discovery. Nat. Rev. Drug Discov. 3, 660-672 (Pubitemid 39173507)
38. Hagel, M., Niu, D., St Martin, T., Sheets, M. P., Qiao, L., Bernard, H., Karp, R. M., Zhu, Z., Labenski, M. T., Chaturvedi, P., Nacht, M., Westlin, W. F., Petter, R. C., and Singh, J. (2011) Selective irreversible inhibition of a protease by targeting a noncatalytic cysteine. Nat. Chem. Biol. 7, 22-24